Demeetra AgBio
PrivateLast Round
Convertible Debt
Apr 1, 2021
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Demeetra AgBio operates in Healthcare & Life Sciences and is based in Lexington, Kentucky. Its latest recorded funding round was a Convertible Debt round in April 2021.
Demeetra AgBio is a biotechnology company that develops advanced genome engineering platforms and integrated services for biopharmaceutical and industrial applications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Demeetra AgBio Comparables
Compare Demeetra AgBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Integra Therapeutics | 77% | |
| Bio-Techne Corporation | 71% | |
| SIRION Biotech | 69% |
For institutional investors. Book with your work email.
Demeetra AgBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Apr 1, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Demeetra AgBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Rapha Capital Management | Convertible Debt |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 2, 2026
Open roles increased to 6, representing 38% of headcount.
- May 20, 2026
Grew 21% QoQ, from 14 to 17 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withOct 6, 2026
Demeetra AgBio, Inc. partners with RIKEN to expand non-commercial academic access to piggyBac research materials, including plasmid vectors, modified cell lines, and animal models, in Japan.
- launchesSep 19, 2026
In Sep '26, Demeetra AgBio, Inc. introduces Harbor-IN Elite, an animal-origin-free transposase mRNA format designed for commercial cell line development programs progressing toward GMP manufacturing.
For institutional investors. Book with your work email.
Demeetra AgBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Demeetra AgBio's valuation, stock price, and market status.
Is Demeetra AgBio a public or private company?
Demeetra AgBio is a private company.
What is the current stock price of Demeetra AgBio?
Demeetra AgBio is a private company, so its shares have no public market price. Caplight tracks Demeetra AgBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Demeetra AgBio worth (valuation)?
Valuation information for Demeetra AgBio is not publicly available.
Can I buy Demeetra AgBio stock?
Demeetra AgBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Demeetra AgBio's last funding round?
Demeetra AgBio's most recent funding round was Convertible Debt on April 1, 2021.
Who are the main investors in Demeetra AgBio?
Key investors in Demeetra AgBio include Rapha Capital Management.
Will Demeetra AgBio IPO soon?
No public IPO plans have been announced for Demeetra AgBio.
How can I track Demeetra AgBio secondary market activity?
Caplight tracks bids, offers, and trades in Demeetra AgBio's shares on secondary markets.